Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy

Vaccine. 2009 Mar 23;27(14):2065-9. doi: 10.1016/j.vaccine.2009.01.113. Epub 2009 Jan 31.

Abstract

The possible interference of tamoxifen with anti-tumor vaccines was studied in a translational view of combined preventive approaches. Tamoxifen treatment of HER-2/neu transgenic mice combined to anti-HER-2/neu cell vaccine did not hamper the efficacy of cancer immunoprevention, and caused a significantly increased production of interferon-gamma. These data suggest that tamoxifen could even have a positive impact on the efficacy of cancer immunoprevention.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use*
  • Carcinoma / immunology
  • Carcinoma / prevention & control*
  • Cells, Cultured
  • Combined Modality Therapy
  • Female
  • Genes, erbB-2 / genetics
  • Genes, erbB-2 / immunology*
  • Interferon-gamma / biosynthesis
  • Mammary Neoplasms, Experimental / immunology
  • Mammary Neoplasms, Experimental / prevention & control*
  • Mice
  • Mice, Transgenic
  • Spleen / immunology
  • Spleen / metabolism
  • Tamoxifen / therapeutic use*
  • Vaccination

Substances

  • Antineoplastic Agents, Hormonal
  • Cancer Vaccines
  • Tamoxifen
  • Interferon-gamma